{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:29:28Z","timestamp":1789946968736,"version":"4.0.1"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2011,10,11]],"date-time":"2011-10-11T00:00:00Z","timestamp":1318291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0025221","type":"journal-article","created":{"date-parts":[[2011,10,11]],"date-time":"2011-10-11T21:41:34Z","timestamp":1318369294000},"page":"e25221","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":38,"title":["Correlation versus Causation? Pharmacovigilance of the Analgesic Flupirtine Exemplifies the Need for Refined Spontaneous ADR Reporting"],"prefix":"10.1371","volume":"6","author":[{"given":"Nora","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Borlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,10,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jama.1995.03530010043033","article-title":"Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group.","volume":"274","author":"DW Bates","year":"1995","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jama.1997.03540280045032","article-title":"The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group.","volume":"277","author":"DW Bates","year":"1997","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/00005650-199110000-00005","article-title":"Characterization of geriatric drug-related hospital readmissions.","volume":"29","author":"LA Bero","year":"1991","journal-title":"Med Care"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.5694\/j.1326-5377.1996.tb122235.x","article-title":"Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs.","volume":"164","author":"JG Dartnell","year":"1996","journal-title":"Med J Aust"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/jama.291.10.1238","article-title":"Actual causes of death in the United States, 2000.","volume":"291","author":"AH Mokdad","year":"2004","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/archinte.165.12.1363","article-title":"Adverse drug event surveillance and drug withdrawals in the United States, 1969\u20132002: the importance of reporting suspected reactions.","volume":"165","author":"DK Wysowski","year":"2005","journal-title":"Arch Intern Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity.","volume":"349","author":"WM Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/bmj.329.7456.44","article-title":"Detection, verification, and quantification of adverse drug reactions.","volume":"329","author":"BH Stricker","year":"2004","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1592\/phco.29.2.138","article-title":"Using secondary data sources for pharmacoepidemiology and outcomes research.","volume":"29","author":"SE Harpe","year":"2009","journal-title":"Pharmacotherapy"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1476-5381.2009.00111.x","article-title":"Neural KCNQ (Kv7) channels.","volume":"156","author":"DA Brown","year":"2009","journal-title":"Br J Pharmacol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s007020050206","article-title":"Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication.","volume":"106","author":"J Kornhuber","year":"1999","journal-title":"J Neural Transm"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-72548-0","article-title":"Arzneiverordnungs-Report 2007","author":"U Schwabe","year":"2008"},{"issue":"46","key":"ref13","first-page":"A 3200","article-title":"Lebersch\u00e4den unter Flupirtin (Aus der UAW-Datenbank).","volume":"104","year":"2007","journal-title":"Dtsch Arztebl"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00002018-200225060-00012","article-title":"Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.","volume":"25","author":"SA Shakir","year":"2002","journal-title":"Drug Saf"},{"key":"ref15","first-page":"295","article-title":"The Environment and Disease: Association or Causation?","volume":"58","author":"AB Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2125.2008.03264.x","article-title":"Causality assessment in hepatotoxicity by drugs and dietary supplements.","volume":"66","author":"R Teschke","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"ref17","first-page":"327","article-title":"Screening.","author":"CH Hennekens","year":"1987"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs\u2013I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.","volume":"46","author":"G Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"ref19","first-page":"374","article-title":"Causal or casual? The role of causality assessment in pharmacovigilance.","volume":"17","author":"RH Meyboom","year":"1997","journal-title":"Drug Saf"},{"key":"ref20","first-page":"102","article-title":"The French pharmacovigilance system: structure and missions.","volume":"29","author":"M Welsch","year":"2000","journal-title":"Presse Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2515\/therapie:2004104","article-title":"Child overdose: the value of the French pharmacovigilance causality assessment method.","volume":"59","author":"M Rajab","year":"2004","journal-title":"Therapie"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2036.2008.03655.x","article-title":"Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury.","volume":"27","author":"M Garcia-Cortes","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"ref23","first-page":"38","article-title":"Use of katadolon in the treatment of abuse headache.","volume":"106","author":"MV Naprienko","year":"2006","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ajg.2008.149","article-title":"How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial.","volume":"104","author":"L Laine","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cld.2007.06.004","article-title":"Nonsteroidal anti-inflammatory drug-induced hepatotoxicity.","volume":"11","author":"GP Aithal","year":"2007","journal-title":"Clin Liver Dis"},{"key":"ref26","first-page":"87","article-title":"On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis.","volume":"63","author":"WM Herrmann","year":"1987","journal-title":"Postgrad Med J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00228-004-0761-0","article-title":"Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case\/non-case study from the French Pharmacovigilance system database.","volume":"60","author":"F Clinard","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1472-8206.2007.00552.x","article-title":"The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database.","volume":"22","author":"A Bate","year":"2008","journal-title":"Fundam Clin Pharmacol"},{"key":"ref29","first-page":"496","article-title":"Analgesic efficacy of flupirtine in primary care of patients with osteoporosis related pain. A multivariate analysis.","volume":"53","author":"JD Ringe","year":"2003","journal-title":"Arzneimittelforschung"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1526-4637.2008.00512.x","article-title":"Combination therapy with flupirtine and opioid: open-label case series in the treatment of neuropathic pain associated with cancer.","volume":"9","author":"CS Goodchild","year":"2008","journal-title":"Pain Med"},{"key":"ref31","first-page":"46","article-title":"[The use of katadolon in patients with spondylogenic dorsalgia].","volume":"106","author":"PR Kamchatnov","year":"2006","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1185\/03007990802579769","article-title":"Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial*.","volume":"24","author":"C Li","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"ref33","first-page":"153","article-title":"Analgesic and muscle tonus normalizing effect of flupirtine retard in chronic back pain. Results of a standardized therapeutic evaluation applying objective methods for measuring pain pressure threshold, pain pressure tolerance and muscle tension.","volume":"149","author":"GH Muller-Schwefe","year":"2008","journal-title":"MMW Fortschr Med"},{"key":"ref34","first-page":"1","article-title":"[Acute treatment of episodic childhood tension-type headache with flupirtine and paracetamol \u2013 a double-blind crossover-study].","volume":"14","author":"R Pothmann","year":"2000","journal-title":"Schmerz"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1742-1241.1985.tb07777.x","article-title":"Use of flupirtine maleate as an analgesic in patients with liver disease.","volume":"39","author":"P Powell-Jackson","year":"1985","journal-title":"Br J Clin Pract"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1124\/dmd.108.024364","article-title":"Investigation of the in vitro metabolism of the analgesic flupirtine.","volume":"37","author":"K Methling","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"ref37","first-page":"67","article-title":"[Pharmacokinetics and biotransformation of the analgesic flupirtine in humans].","volume":"35","author":"P Hlavica","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"ref38","first-page":"1343","article-title":"Dose-proportional plasma levels of the analgesic flupirtine maleate in man. Application of a new HPLC assay.","volume":"42","author":"G Niebch","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0014-5793(00)01923-2","article-title":"Protection of mitochondrial integrity from oxidative stress by the triaminopyridine derivative flupirtine.","volume":"481","author":"T Schluter","year":"2000","journal-title":"FEBS Lett"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ana.10143","article-title":"Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic.","volume":"51","author":"S Dhar","year":"2002","journal-title":"Ann Neurol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0922-4106(94)90006-X","article-title":"The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-methyl-D-aspartate and gp120 of HIV-1.","volume":"288","author":"S Perovic","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.neuropharm.2006.03.024","article-title":"Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures.","volume":"51","author":"F Boscia","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00702-002-0784-6","article-title":"Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation.","volume":"110","author":"M Gassen","year":"2003","journal-title":"J Neural Transm"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1358\/dot.2002.38.1.660505","article-title":"Neuroprotective effect of flupirtine in prion disease.","volume":"38","author":"HC Schroder","year":"2002","journal-title":"Drugs Today (Barc )"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0025221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T11:47:35Z","timestamp":1686397655000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0025221"}},"subtitle":[],"editor":[{"given":"Antje","family":"Timmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,10,11]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,10,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0025221","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,11]]}}}